HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors
Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Intratumoral Injection of HP007 Injection as Monotherapy in Patients With Relapsed or Refractory Advanced Solid Tumors, and to Explore the Preliminary Efficacy of HP007
This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of HP007 monotherapy in patients with advanced malignant solid tumors.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Niannian Wang, Project Manager
- 전화번호: +86 13161547878
- 이메일: niannian_wang@junshipharma.com
연구 장소
-
-
Jilin
-
Changchun, Jilin, 중국, 130000
- 모병
- The First Hospital of Jilin University
-
연락하다:
- Yanhua Ding, Chief Physician
- 이메일: dingyanh@jlu.edu.cn
-
수석 연구원:
- Yanhua Ding, Chief Physician
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male/female, 18-75 years inclusive.
- Histologically-confirmed unresectable advanced tumors (breast cancer, HNSCC, cutaneous melanoma, prostate cancer, HCC, etc.);
- no effective standard therapy or disease relapse/metastasis post-standard-of-care.
- ECOG PS 0-1;
- expected survival ≥3 months.
- At least 1 measurable lesion by RECIST 1.1. Lesion in prior radiation field must have confirmed progression ≥4 weeks post-radiation. Prostate cancer subjects must meet PCWG3 progression criteria.
- At least one lesion suitable for repeated intratumoral injection.
- Adequate hematopoietic and organ function:
- Males and females of child-bearing potential agree effective contraception from ICF signature to 3 months after last dose.
- Voluntarily sign ICF and comply with study procedures.
Exclusion Criteria:
-
Past/current medical conditions
- CNS or leptomeningeal metastasis.
- Residual toxicity from prior anti-tumor therapy >Grade 1 (CTCAE 6.0), except alopecia and Grade 2 peripheral neuropathy without safety risk.
- Poorly controlled pleural / ascitic / pericardial effusion requiring local intervention or repeated drainage.
- Active autoimmune disease or high-risk history of recurrence; organ transplant with immunosuppression.
- Interstitial lung disease / non-infectious pneumonitis; pulmonary embolism within prior 12 weeks.
- Severe cardio-cerebrovascular events within 6 months; QTcF ≥470 msec; LVEF ≤50%; NYHA ≥III heart failure; history of long-QT syndrome or ongoing QTc-prolonging drugs.
- Uncontrolled hypertension (SBP>160 mmHg and/or DBP>100 mmHg) or other uncontrolled systemic diseases.
- High bleeding risk / coagulation disorders: inherited/acquired bleeding-thrombotic predisposition; major bleeding within 3 months; thrombolytics within 10 days; ongoing anticoagulant/antiplatelet therapy (except heparin for CVC patency).
- Immunodeficiency; history of solid-organ or hematopoietic stem-cell transplantation.
- Active TB within past 5 years.
- Severe infection / trauma / GI perforation / fistula / tumor vascular invasion / bowel obstruction within 4 weeks; active infection or antibiotic use within prior 2 weeks (prophylaxis allowed); unexplained fever >38.5 ℃ (tumor-related fever may be allowed per Investigator judgment).
- Other active malignancy within 3 years, except: cervical carcinoma in-situ, local basal-cell carcinoma, or malignancies cured ≥5 years without recurrence.
-
Prior medications & treatments
- Local radiotherapy completed <1 week before first dose; >30% bone-marrow / extensive-field radiotherapy completed <4 weeks before first dose.
- Anti-tumor therapy within 4 weeks or less than 5 half-lives (whichever shorter).
- Systemic corticosteroids (>10 mg prednisone equivalent/day) or other immunosuppressants within 14 days.
- Prior immunotherapy with irAEs ≥Grade 3.
- Prior systemic TLR-agonist treatment (topical TLR agonists e.g. imiquimod permitted).
- Vaccination within 1 month prior to enrolment.
-
Allergy, general status & others
- Severe hypersensitivity (CTCAE 6.0 ≥Grade 3) to any investigational product component.
- Active HBV / HCV, positive syphilis or HIV serology.
- Participated in another interventional clinical trial within 4 weeks.
- Major surgery within 4 weeks before screening or planned major surgery during study.
- Alcohol / illicit-drug / substance abuse within 12 months.
- Documented neurological/psychiatric disorders leading to poor compliance.
- Pregnant or lactating females.
- Subjects judged unsuitable by the Investigator for any other reason.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: HP007
Participate will recepit HP007 monotherpy with 4 dose groups |
Participate will recepit HP007 monotherpy with 4 dose groups |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
DLT
기간: up to one year
|
Safety endpoints: incidence and severity of DLT |
up to one year
|
|
AE
기간: up to two years
|
Safety endpoints: incidence and severity of adverse events (AE); Abnormal changes in laboratory and other tests with clinical significance |
up to two years
|
|
SAE
기간: up to two years
|
Safety endpoints: incidence and severity of serious adverse events (SAE); Abnormal changes in laboratory and other tests with clinical significance |
up to two years
|
|
MTD
기간: up to one year
|
Maximum tolerated dose (MTD) |
up to one year
|
|
RP2D
기간: up to one year
|
Recommended dose for phase II trial |
up to one year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
ORR
기간: up to two years
|
Efficacy endpoints: Objective response rate (ORR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
DOR
기간: up to two years
|
Efficacy endpoints: Duration of response (DOR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
DCR
기간: up to two years
|
Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
PFS
기간: up to two years
|
Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
OS
기간: up to two years
|
Efficacy endpoints: Overall survival (OS) |
up to two years
|
|
Peak concentration(Cmax)
기간: up to two years
|
The pharmacokinetic parameters of WJ47156:peak concentration (Cmax) |
up to two years
|
|
the time to receive Cmax(Tmax)
기간: up to two years
|
The pharmacokinetic parameters of HP007:the time to receive Cmax (Tmax) |
up to two years
|
|
Area Under the plasma concentration-time curve (AUC0-t, AUC0-∞)
기간: up to two years
|
The pharmacokinetic parameters of HP007 :area under the plasma concentration-time curve (AUC0-t, AUC0-∞) |
up to two years
|
|
Volume of distribution (Vd)
기간: up to two years
|
The pharmacokinetic parameters of HP007 :Volume of distribution (Vd) |
up to two years
|
|
Rate of clearance (C)
기간: up to two years
|
The pharmacokinetic parameters of HP007 :Rate of clearance (CL) |
up to two years
|
|
Terminal half-life (t1/2)
기간: up to two years
|
The pharmacokinetic parameters of WJ47156 :terminal half-life (t1/2), |
up to two years
|
|
Steady-state peak concentration(Cmax,ss)
기간: up to two years
|
The pharmacokinetic parameters of HP007 :steady-state peak concentration(Cmax,ss) for the main PK parameters for multiple dose |
up to two years
|
|
Plasma trough concentration at steady state(Cmin,ss)
기간: up to two years
|
The pharmacokinetic parameters of HP007:Plasma trough concentration at steady state(Cmin,ss) for the main PK parameters for multiple dose |
up to two years
|
|
Accumulation ratio for AUC
기간: up to two years
|
The pharmacokinetic parameters of HP007:Accumulation ratio of area-under-the-curve, defined as steady-state AUC within one dosing interval divided by Day 1 AUC (typically AUC₀-₂₄h). It characterizes overall systemic exposure accumulation over the dosing cycle, used for efficacy and total exposure assessment. |
up to two years
|
|
the time to receive Cmax at steady state(Tmax,ss)
기간: up to two years
|
The pharmacokinetic parameters of HP007 :the time to receive Cmax at steady state(Tmax,ss)for the main PK parameters for multiple dose) |
up to two years
|
|
Area Under the plasma concentration-time curve at steady state (AUC0-t, ss)
기간: up to two years
|
The pharmacokinetic parameters of HP007:area under the plasma concentration-time curve at steady state (AUC0-t, ss)for the main PK parameters for multiple dose) |
up to two years
|
|
ADA
기간: up to two years
|
The incidence and changes of anti-drug antibody (ADA) after treatment were observed |
up to two years
|
|
Nab
기간: up to two years
|
The incidence and changes of neutralizing antibody (Nab) after treatment were observed |
up to two years
|
|
Cytokines
기간: up to one year
|
The changes of serum cytokines (IFN-α, IFN-γ, IL-6, IL-10, and chemokines IFN-γ-inducible protein 10 (IP-10) and TNF-α )in peripheral blood before and after treatment were observed |
up to one year
|
|
Subtype of lymphocyte
기간: up to one year
|
Flow cytometry was used to detect the changes in lymphocyte subsets in peripheral blood before and after treatment |
up to one year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- HP007CH101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .